找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Current Management of Melanoma; Ferdinando Cafiero,Franco De Cian Book 2021 Springer Nature Switzerland AG 2021 surgery treatment.sentinel

[復(fù)制鏈接]
樓主: fungus
41#
發(fā)表于 2025-3-28 17:50:21 | 只看該作者
Slips of Paper and Performance Artrocedure. Lymph node involvement is diagnosed in different ways, most frequently after sentinel lymph node biopsy (SLNB), but some patients may present clinical evident metastases at diagnosis or during the follow-up. In the case of positive SLNB, about 15–20% of patients have additional metastatic
42#
發(fā)表于 2025-3-28 21:50:28 | 只看該作者
https://doi.org/10.1007/978-3-319-45772-7mphocele, hematomas and lymphedema. Secondary lymphedema of the limbs is a debilitating and progressive condition that commonly occurs following melanoma treatment. The technique known as lymphatic microsurgical preventive healing approach (LYMPHA) is able to prevent secondary lymphedema following l
43#
發(fā)表于 2025-3-28 23:08:57 | 只看該作者
44#
發(fā)表于 2025-3-29 06:25:50 | 只看該作者
Zheng Liu,Shuting Guo,Tao Li,Wenyan Chen increase in surgical indications also for patients with metastatic melanoma. The surgical indications in this disease setting can be summarized as: collection of biological material; treatment of oligometastatic disease; treatment beyond progression; palliation surgery. In selected cases, surgical
45#
發(fā)表于 2025-3-29 10:59:38 | 只看該作者
Peizhong Yang,Lihua Zhou,Hongmei Chenith resected, high-risk melanoma. After a 20-year era of adjuvant interferon, checkpoint inhibitor immunotherapy and BRAF+MEK inhibitors revolutionized the management of melanoma in everyday clinical practice. In this review, we summarize the current state of the art of the adjuvant treatment of hig
46#
發(fā)表于 2025-3-29 13:09:00 | 只看該作者
47#
發(fā)表于 2025-3-29 16:06:48 | 只看該作者
48#
發(fā)表于 2025-3-29 22:43:09 | 只看該作者
49#
發(fā)表于 2025-3-30 02:03:36 | 只看該作者
Updates in Surgeryhttp://image.papertrans.cn/d/image/241238.jpg
50#
發(fā)表于 2025-3-30 06:09:33 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2026-1-21 15:29
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
宜章县| 舟山市| 阳曲县| 昂仁县| 龙山县| 新龙县| 岗巴县| 麻阳| 萨嘎县| 九江县| 米泉市| 湘潭县| 洛宁县| 沙河市| 云阳县| 汾阳市| 华池县| 山丹县| 肇庆市| 雷波县| 海晏县| 福建省| 丹棱县| 洛宁县| 孝昌县| 西充县| 鲁山县| 海盐县| 雷州市| 江油市| 漠河县| 郓城县| 凤凰县| 怀宁县| 小金县| 叙永县| 嵊泗县| 邯郸市| 武邑县| 镇赉县| 东港市|